Affordable Access

The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.

Authors
  • Schwarzlose-Schwarck, Sandra
  • Scholz, Christian W
  • Regierer, Anne C
  • Martus, Peter
  • Neumann, Christian
  • Habbel, Piet
  • Liu, Hongyu
  • Zang, Chuanbing
  • Schefe, Jan-Hendrik
  • Schulz, Carsten-Oliver
  • Possinger, Kurt
  • Eucker, Jan
Type
Published Article
Journal
Anticancer Research
Publisher
International Institute of Anticancer Research
Publication Date
Aug 01, 2012
Volume
32
Issue
8
Pages
3435–3441
Identifiers
PMID: 22843927
Source
Medline
License
Unknown

Abstract

Carboplatin and everolimus is a well-tolerated combination for heavily pre-treated metastatic breast cancer. Everolimus (10 mg/d) and carboplatin (AUC2 weekly) were defined as the MTD. This dose is currently being employed in an ongoing phase II trial.

Report this publication

Statistics

Seen <100 times